阿德福韦酯治疗慢性乙型肝炎的疗效观察

Adefovir dipivoxil treatment of chronic hepatitis B

目的观察阿德福韦酯治疗慢性乙型肝炎患者的临床疗效及不良反应。方法选择慢性乙型肝炎患者54例,分成治疗组和对照组,对照组进行一般的保肝护肝治疗,治疗组口服阿德福韦酯2年加保肝护肝治疗。结果治疗组HBV-DNA和HBeAg的转阴率分别为71.43%和42.86%,而对照组为15.38%和15.33%,两组比较差异有显著性(P<0.05),所有病例均未见严重不良反应。结论阿德福韦酯是一种有效的抗HBV药物,能有效控制病毒复制,改善肝功能,长期用药安全性及耐受性良好。

Objective To observe the treatment of chronic hepatitis B patients with adefovir dipivoxil the clinical efficacy and adverse reactions.Methods 54 patients with chronic hepatitis B patients were divided into treatment group and control group and control group for general liver protection Liver treatment,the treatment group was treated with adefovir dipivoxil for 2 years plus Liver treatment.Results The treatment group of HBV-DNA and HBeAg seroconversion rates were 71.43% and 42.86%,while the control group was 15.38% and 15.33%,the difference was significant （P〈0.05）,all cases were no serious adverse reactions.Conclusion Adefovir dipivoxil is an effective anti-HBV drugs can effectively control viral replication,improve liver function,long-term drug safety and well-tolerated.